- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
FDA Approves Hemlibra for Hemophilia A With or Without Factor VIII Inhibitors
With its new FDA approval, Hemlibra (emicizumab-kxwh), a bispecific factor IXa- and factor X-directed antibody, has become the first prophylactic treatment for patients with hemophilia A with or without factor VIII inhibitors.
With its new FDA approval, Hemlibra (emicizumab-kxwh), a bispecific factor IXa- and factor X-directed antibody, has become the first prophylactic treatment for patients with hemophilia A with or without factor VIII inhibitors.
In November 2017, Hemlibra was first approved by the FDA for hemophilia A, a congenital factor VIII deficiency, with inhibitors. After the results of a pair of phase 3 trials, HAVEN 3 and HAVEN 4, Hemlibra was approved with the additional indication for use without factor VIII inhibitors.
“The approval of Hemlibra introduces a new class of medicine for [hemophilia A] the first time in nearly 20 years,” said Michael Callaghan, MD, at Children’s Hospital of Michigan in a statement.
HAVEN 3 was a randomized, open-label trial in patients with hemophilia A without factor VIII inhibitors. Patients who received Hemlibra once weekly or biweekly had a 96% and 97% reduction in treated bleeds, respectively, versus those with no prophylaxis.
In addition, 55.6% and 60% patients treated with Hemlibra once and twice weekly, respectively, experienced no treated bleeds compared with 0% in patients with no prophylaxis. Hemlibra prophylaxis also resulted in a 95% reduction in all bleeds in once-weekly administration and 94% reduction for biweekly administration. The results of HAVEN 3 led to the priority review and breakthrough therapy designation from the FDA.
HAVEN 4 also helped to evaluate Hemlibra dosing given every 4 weeks. The less frequent dosing schedule adds more convenience for patients in need of prophylaxis. In this study, patients with or without factor VIII inhibitors given Hemlibra every 4 weeks experienced no treated bleeds, and approximately 90% of patients experienced 3 or fewer treated bleeds.
The adverse events (AEs) associated with Hemlibra were well tolerated, with the most common AEs being injection-site reactions, headache, and joint pain. The clinical effectiveness of Hemlibra across all bleed-related endpoints marks Hemlibra as a significant preventative treatment option for patients, while only requiring weekly to monthly administrations.
“Today’s approval of Hemlibra reflects our commitment to groundbreaking science and the development of medicines with the potential to redefine the standard of care” said Sandra Horning, MD, chief medical officer and head of Global Product Development in a statement.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
November 21st 2023Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Odevixibat Safe for Alagille Syndrome Based on Hepatic Changes
November 8th 2023Pooled phase 3 data presented at North American Society for Pediatric Gastroenterology, Hepatology & Nutrition 2023 support the benefit-risk profile of the ileal bile acid transport inhibitor in treating the rare liver disease.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
